Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy

Journal of Nuclear Cardiology

Volumn 16, Issue 1, 2009, Pages 92-96

  Sciagrà, Roberto ^a   Sotgia, Barbara ^a   Olivotto, Iacopo ^b   Cecchi, Franco ^b   Nistri, Stefano ^b   Camici, Paolo G ^c   Pupi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Atrial fibrillation; Coronary blood flow; Dipyridamole; Hypertrophic cardiomyopathy; Myocardial perfusion imaging; PET

Indexed keywords

AMMONIA; DIPYRIDAMOLE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CHRONIC DISEASE; CORONARY ARTERY BLOOD FLOW; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART SIZE; HUMAN; HYPEREMIA; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE; COMORBIDITY; INCIDENCE; ITALY; METHODOLOGY; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; ATRIAL FIBRILLATION; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; COMORBIDITY; FEMALE; HUMANS; HYPEREMIA; INCIDENCE; ITALY; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 67649963696     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12350-008-9005-5     Document Type: Article

References (21)

1. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002;287:1308-20.
2. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-24.
3. Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D'Alessandro G, et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004;94:895-900.
4. Camici PG, Chiriatti G, Lorenzoni R, Bellina CR, Gistri R, Italiani G, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: A study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991;17:879-86.
5. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-40.
6. Lorenzoni R, Gistri R, Cecchi F, Olivotto I, Chiriatti G, Elliott P, et al. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. Am Heart J 1998;136:972-81.
7. Choudhury L, Elliott P, Rimoldi O, Ryan M, Lammertsma AA, Boyd H, et al. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Basic Res Cardiol 1999;94:49-59.
8. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.
9. Olivotto I, Cecchi F, Gistri R, Lorenzoni R, Chiriatti G, Girolami F, et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006;47:1043-8.
10. Bellina CR, Parodi O, Camici PG, Salvadori PA, Taddei L, Fusani L, et al. Simultaneous in vitro and in vivo validation of 13 N-Ammonia for the assessment of regional myocardial blood flow. J Nucl Med 1990;31:1335-43.
11. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990;15:1032-42.
12. Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, et al. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Circulation 1997;95:1686-744.
13. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005;111:2033-41.
14. Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol 2006;98:960-5.
15. Olivotto I, Maron BJ, Cecchi F. Pathophysiology and clinical consequences of atrial fibrillation in hypertrophic cardiomyopathy. In: Maron BJ, editor. Diagnosis and management of hypertrophic cardiomyopathy. Cambridge, MA: Blackwell Futura; 2004. p. 105-20.
16. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: The interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84:476-82.
17. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia. Hum Pathol 2000;31:988-98.
18. Mehta RH, Dabbous OH, Granger CB, Kuznetsova P, Kline-Rogers EM, Anderson FA Jr, et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol 2003;92:1031-6.
19. Pedersen OD, Abildstrøm SZ, Ottesen MM, Rask-Madsen C, Bagger H, Køber L, et al. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J 2006;27:290-5.
20. Bunch TJ, Chandrasekaran K, Ehrsam JE, Hammill SC, Urban LH, Hodge DO, et al. Prognostic significance of exercise induced arrhythmias and echocardiographic variables in hypertrophic cardiomyopathy. Am J Cardiol 2007;99:835-8.
21. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993;72:970-2.